Core Scientific (NASDAQ:CORZ) Stock Rating Reaffirmed as Buy by BTIG Research

Core Scientific (NASDAQ:CORZ)‘s stock had its “buy” rating restated by equities researchers at BTIG Research in a research report issued on Thursday, Benzinga reports. They currently have a $38.00 price target on the stock. BTIG Research’s price target points to a potential upside of 162.98% from the company’s current price.

Several other equities analysts have also issued reports on the company. Compass Point reiterated a “buy” rating and issued a $36.00 price objective on shares of Core Scientific in a research report on Wednesday, July 29th. Needham & Company LLC raised their target price on shares of Core Scientific from $29.00 to $35.00 and gave the stock a “buy” rating in a report on Wednesday, July 29th. Citigroup reaffirmed a “market outperform” rating on shares of Core Scientific in a research note on Wednesday. Canaccord Genuity Group upped their price target on shares of Core Scientific from $30.00 to $36.00 and gave the company a “buy” rating in a report on Wednesday, July 29th. Finally, Freedom Capital upgraded shares of Core Scientific from a “hold” rating to a “strong-buy” rating in a report on Thursday, July 30th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Core Scientific has a consensus rating of “Moderate Buy” and an average target price of $31.36.

Core Scientific Stock Performance

NASDAQ:CORZ traded up $0.94 on Thursday, reaching $14.45. The company’s stock had a trading volume of 33,742,997 shares, compared to its average volume of 12,695,081. Core Scientific has a 1-year low of $12.31 and a 1-year high of $30.46. The business’s 50-day moving average price is $17.58 and its two-hundred day moving average price is $21.05. The firm has a market cap of $4.64 billion, a PE ratio of -3.27 and a beta of 5.49.

Core Scientific (NASDAQ:CORZ) last released its quarterly earnings results on Tuesday, July 28th. The company reported ($3.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($3.26). The firm had revenue of $164.20 million during the quarter, compared to the consensus estimate of $144.83 million. As a group, sell-side analysts expect that Core Scientific will post -1.36 EPS for the current year.

Insider Activity

In other Core Scientific news, Director Eric Weiss acquired 6,000 shares of the stock in a transaction dated Tuesday, September 15th. The shares were bought at an average cost of $16.33 per share, for a total transaction of $97,980.00. Following the completion of the acquisition, the director directly owned 265,262 shares of the company’s stock, valued at approximately $4,331,728.46. This trade represents a 2.31% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Todd DuChene sold 10,000 shares of the business’s stock in a transaction on Monday, October 12th. The stock was sold at an average price of $15.12, for a total transaction of $151,200.00. Following the completion of the sale, the insider directly owned 1,159,668 shares in the company, valued at approximately $17,534,180.16. This represents a 0.85% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have acquired 19,000 shares of company stock worth $342,290 and have sold 100,000 shares worth $1,881,300. 1.70% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Core Scientific

Large investors have recently modified their holdings of the business. BlackRock Inc. acquired a new stake in shares of Core Scientific in the second quarter valued at about $719,649,000. Jericho Capital Asset Management L.P. boosted its position in Core Scientific by 11.4% during the fourth quarter. Jericho Capital Asset Management L.P. now owns 13,038,619 shares of the company’s stock valued at $189,842,000 after purchasing an additional 1,338,796 shares during the last quarter. Bank of America Corp DE boosted its position in Core Scientific by 412.5% during the first quarter. Bank of America Corp DE now owns 4,806,363 shares of the company’s stock valued at $71,903,000 after purchasing an additional 3,868,535 shares during the last quarter. Clearline Capital LP boosted its position in Core Scientific by 274.2% during the fourth quarter. Clearline Capital LP now owns 4,689,443 shares of the company’s stock valued at $68,278,000 after purchasing an additional 3,436,127 shares during the last quarter. Finally, Apollo Management Holdings L.P. bought a new position in Core Scientific in the second quarter valued at approximately $115,671,000.

Core Scientific News Roundup

Here are the key news stories impacting Core Scientific this week:

• Positive Sentiment: Analysts reaffirm bullish ratings and high price targets. Canaccord Genuity reaffirmed a “buy” rating with a $36 target, while BTIG Research maintained its “buy” rating with a $38 target. Cantor Fitzgerald also reiterated an “overweight” rating and a $39 target. These targets imply substantial potential upside from recent trading levels and reinforce expectations that Core Scientific’s AI/HDC infrastructure strategy can generate significant growth.
• Positive Sentiment: Needham maintained its $35 target. The firm reiterated its outlook even as investors monitor credit pressure affecting CoreWeave, Core Scientific’s tenant. Maintaining the target suggests Needham believes the long-term data-center opportunity remains attractive despite customer-related risks. Needham reiterates $35 Core Scientific target as tenant CoreWeave faces credit pressure
• Neutral Sentiment: Third-quarter results are scheduled for November 5. Core Scientific will release fiscal third-quarter 2026 results before the market opens and hold a conference call at 8:30 a.m. Eastern time. The event provides a near-term catalyst, particularly for updates on AI/HDC colocation demand, customer concentration, capacity expansion and financial performance. Core Scientific schedules third-quarter 2026 earnings release
• Negative Sentiment: An insider sold $151,200 of stock. Director or insider Todd DuChene sold 10,000 shares at an average price of $15.12, reducing his direct holdings by approximately 0.85%. He still retains a sizable position, but the transaction may weigh modestly on sentiment because it signals some insider profit-taking.
• Negative Sentiment: CoreWeave’s credit concerns remain a risk. Because Core Scientific relies on large data-center customers, financial pressure at CoreWeave could raise concerns about customer concentration, contract execution or payment risk. Investors will likely seek clarification on this issue during the upcoming earnings call.

Core Scientific Company Profile

Core Scientific, Inc is a digital infrastructure company that develops and operates data centers in the United States. Its business has historically centered on cryptocurrency mining, particularly the processing of transactions on the Bitcoin network, while also providing hosting and infrastructure services to other mining and technology customers.

The company is expanding its data center capabilities to support high-performance computing and artificial intelligence workloads. Its services include data center operations, power and equipment management, hosting, and related infrastructure support for customers that require substantial computing capacity.

Core Scientific was founded in 2017 and became a publicly traded company through a business combination in 2022.